Westrick R J, Ginsburg D
Department of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA.
J Thromb Haemost. 2009 Jul;7 Suppl 1:132-5. doi: 10.1111/j.1538-7836.2009.03362.x.
Most inherited hemostatic disorders exhibit incomplete penetrance and variable expressivity, which can be because of genetic or environmental interactions. This wide phenotypic variability for a given disease can be partly explained by modifier gene interactions. Modifier gene interactions have been described for VWD, TTP and venous thrombosis associated with the factor V Leiden mutation. We have exploited advances in mouse genetics in an effort to identify novel genetic loci that may serve as candidate genetic modifiers for bleeding and thrombosis in humans. We have identified several loci affecting plasma VWF levels and have identified and characterized mouse models of ADAMTS13 deficiency and Factor V Leiden that could be useful for identifying novel genes contributing to thrombosis risk in humans.
大多数遗传性止血障碍表现出不完全外显率和可变表达性,这可能是由于基因或环境相互作用所致。给定疾病的这种广泛表型变异性部分可由修饰基因相互作用来解释。已针对血管性血友病(VWD)、血栓性血小板减少性紫癜(TTP)以及与因子V莱顿突变相关的静脉血栓形成描述了修饰基因相互作用。我们利用小鼠遗传学的进展来努力鉴定可能作为人类出血和血栓形成候选遗传修饰因子的新基因座。我们已经鉴定出几个影响血浆血管性血友病因子(VWF)水平的基因座,并鉴定和表征了含凝血酶敏感蛋白基的解聚素样金属蛋白酶13(ADAMTS13)缺乏症和因子V莱顿的小鼠模型,这些模型可能有助于鉴定导致人类血栓形成风险的新基因。